Inoperable early-stage primary and early recurrent non-small cell lung cancer: outcomes of a mono-institutional experience using a moderate hypofractionated schedule.
3D-RT
Hypofractionation
NSCLC
Radiation therapy
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
26
06
2018
accepted:
20
08
2018
pubmed:
5
9
2018
medline:
30
1
2019
entrez:
5
9
2018
Statut:
ppublish
Résumé
Patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) may beneficiate of a hypofractionated radiation therapy in order to intensificate the treatment and to reduce the number of hospital access. From 2007 to 2015, 27 patients with early-stage primary or limited loco-regional recurrent (T2a > 4 cm, T2b N0 or T1-2 N1M0) NSCLC were treated. All patients were medically inoperable or refused surgery and were treated with 60 Gy in 20 fractions, 5 times per week. Thirteen (48.1%) presented limited recurrence after surgery and 14 (51.9%) primary disease. Median follow-up was 34 months. Twelve patients achieved a CR (44.4%) and 8 a PR (29.6%) with a tumour response rate of 74%. Median overall survival (OS) and 2-year OS were 34 months and 63.0%, respectively. Median and 2-year loco-regional progression-free survival (LR-PFS) were 31 months and 51.4%, respectively. Survival outcomes were statistically favourable in patients with partial or complete response with respect to patients with stable or progressive disease, whereas stage (N0 vs N1) and primary or relapse/recurrent disease not. No cases of acute toxicity > grade 2 were observed. Seven patients (25.9%) presented grade 2 late toxicities. Sixty Gy in 20 fractions is well tolerated and achieves good clinical outcomes in early primary or recurrent NSCLC patients. A greater number of patients and a longer follow-up are necessary to confirm the results obtained with our treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) may beneficiate of a hypofractionated radiation therapy in order to intensificate the treatment and to reduce the number of hospital access.
METHODS
METHODS
From 2007 to 2015, 27 patients with early-stage primary or limited loco-regional recurrent (T2a > 4 cm, T2b N0 or T1-2 N1M0) NSCLC were treated. All patients were medically inoperable or refused surgery and were treated with 60 Gy in 20 fractions, 5 times per week. Thirteen (48.1%) presented limited recurrence after surgery and 14 (51.9%) primary disease.
RESULTS
RESULTS
Median follow-up was 34 months. Twelve patients achieved a CR (44.4%) and 8 a PR (29.6%) with a tumour response rate of 74%. Median overall survival (OS) and 2-year OS were 34 months and 63.0%, respectively. Median and 2-year loco-regional progression-free survival (LR-PFS) were 31 months and 51.4%, respectively. Survival outcomes were statistically favourable in patients with partial or complete response with respect to patients with stable or progressive disease, whereas stage (N0 vs N1) and primary or relapse/recurrent disease not. No cases of acute toxicity > grade 2 were observed. Seven patients (25.9%) presented grade 2 late toxicities.
CONCLUSION
CONCLUSIONS
Sixty Gy in 20 fractions is well tolerated and achieves good clinical outcomes in early primary or recurrent NSCLC patients. A greater number of patients and a longer follow-up are necessary to confirm the results obtained with our treatment.
Identifiants
pubmed: 30178173
doi: 10.1007/s11547-018-0934-z
pii: 10.1007/s11547-018-0934-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
58-64Références
Semin Surg Oncol. 2000 Mar;18(2):124-36
pubmed: 10657914
Semin Radiat Oncol. 1996 Apr;6(2):98-104
pubmed: 10717168
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):703-10
pubmed: 11020567
Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):23-33
pubmed: 11163494
Thorax. 2001 Aug;56(8):628-38
pubmed: 11462066
Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1047-57
pubmed: 11958901
Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1014-23
pubmed: 12419427
Semin Surg Oncol. 2003;21(2):91-7
pubmed: 14508859
Radiat Oncol. 2006 Nov 01;1:42
pubmed: 17078878
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
pubmed: 18287387
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Front Radiat Ther Oncol. 2010;42:94-114
pubmed: 19955796
J Thorac Oncol. 2010 May;5(5):620-30
pubmed: 20354456
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):459-65
pubmed: 20385455
Lancet Oncol. 2012 Aug;13(8):802-9
pubmed: 22727222
Curr Oncol. 2012 Aug;19(4):e264-9
pubmed: 22876155
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):e157-63
pubmed: 23182393
Radiother Oncol. 2013 Oct;109(1):8-12
pubmed: 24094626
Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):603-11
pubmed: 25052562
J Natl Cancer Inst. 2014 Jul 29;106(8):null
pubmed: 25074417
Clin Transl Oncol. 2017 Apr;19(4):440-447
pubmed: 27553602
Acta Oncol. 1988;27(2):131-46
pubmed: 3390344
Cancer. 1980 Feb 15;45(4):698-702
pubmed: 6244073
Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3
pubmed: 7677489
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792